• contents
  • main menu
  • head menu
  • footer menu

KM Biologics

MENU
  • ABOUT USopen
    • ABOUT US
    • KM Biologics at a Glance
    • Our Business
    • Product History
    • President’s Message
    • Our Philosophy
    • Meiji Group Sustainability
    • Board of Directors
    • Locations
  • INNOVATIONSopen
    • INNOVATIONS
    • Our Scientists
  • PRODUCTSopen
    • PRODUCTS
    • Vaccines
    • Antitoxins and Antivenoms
    • Blood Plasma Products
  • NEWS
  • CONTACT US

Supporting the healthy future of people around the world with biotechnology

KM Biologics at a Glance

Product History

Innovations

Our Scientists

Products

Pharmaceuticals

Vaccines
Antitoxins and Antivenoms
Blood Plasma Products

Veterinary Vaccines

Meiji Animal Health Co., Ltd.New window will be opened.
KM Biologics has transferred its animal health business to its subsidiary, Meiji Animal Health Co., Ltd.

Contact us to unfold a world of possibilities

CONTACT US

NEWS

Mar. 4, 2025
Meiji Seika Pharma Invests in Osivax SAS
Jan. 27, 2025
Japanese Government Delivers KM Biologics' Mpox Vaccine to the Democratic Republic of the Congo
Nov. 20, 2024
KM Biologics Receives WHO Emergency Use Listing for its Mpox Vaccine
Sep. 10, 2024
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan
Jul. 10, 2024
KM Biologics is Selected Through an Open Call for Conducting the ”Large-scale Vaccine Clinical Study Project“ by the Ministry of Health, Labour and Welfare
All news releases
Meiji HoldingsOpen new window

KM Biologics is a member of the Meiji Group. Learn more about Meiji Holdings.

Investor Relations
Investor RelationsOpen new window
News
NewsOpen new window

Page Top

  • JAPANESE
  • Terms and Conditions
  • Privacy Policy
  • © KM Biologics All Rights Reserved.
Meiji Holdings Co., Ltd.New window will be opened.